Arixtra

Arixtra Injection, Sc Injection, Solution For Injection In Pre-filled Syringe, Solution, Subcutaneous Solution

Arixtra, a synthetic pentasaccharide, acts as a selective inhibitor of activated factor X. It works by binding selectively to antithrombin III and potentiates the neutralisation of factor Xa. This will interrupt the blood coagulation cascade and inhibit both thrombin formation and thrombus development.

Uses

Prophylaxis Of Deep Vein Thrombosis- Arixtra is used for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):

  • In patients undergoing hip fracture surgery, including extended prophylaxis;
  • In patients undergoing hip replacement surgery;
  • In patients undergoing knee replacement surgery;
  • In patients undergoing abdominal surgery who are at risk for thromboembolic complications.

Treatment Of Acute Deep Vein Thrombosis: Arixtra is used for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium.

Treatment Of Acute Pulmonary Embolism: Arixtra is used for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.

Arixtra is also used to associated treatment for these conditions: Acute Pulmonary Embolism, Deep Vein Thrombosis, Non ST Segment Elevation Myocardial Infarction (NSTEMI), ST Elevation Myocardial Infarction (STEMI), Unstable Angina Pectoris, Acute, superficial, symptomatic Vein Thrombosis

Arixtra

Trade Name Arixtra
Generic Fondaparinux
Fondaparinux Other Names Natural heparin pentasaccharide
Weight 2.5mg/0.5ml, , 5mg/ml, 10mg/0.8ml, 5mg/0.4ml, 7.5mg/0.6ml
Type Injection, Sc Injection, Solution For Injection In Pre-filled Syringe, Solution, Subcutaneous Solution
Formula C31H53N3O49S8
Weight Average: 1508.263
Monoisotopic: 1506.951330709
Protein binding

94% in vitro protein binding specifically to ATIII

Therapeutic Class Parenteral anti-coagulants
Manufacturer Glaxosmithkline, Aspen Pharma Trading Limited (aptl), Aspen Badoldesloe
Available Country India, Bangladesh, Canada, Saudi Arabia, Philippines, United States, Netherlands, Switzerland,
Last Updated: June 23, 2021 at 9:09 am

Structure

Arixtra
Fondaparinux Structure

Dosage

Arixtra dosage

Superficial vein thrombosis: 2.5 mg once daily for 30-45 days.

Venous thromboembolism

  • 50-100 kg: 7.5 mg once daily;
  • >100 kg: 10 mg once daily.
  • Treatment duration: 5-9 days, or until oral anticoagulation is established.

Prophylaxis of deep vein thrombosis in abdominal and orthopaedic surgery: 2.5 mg once daily, starting 6-8 hr after surgery, continue for at least 5-9 days. In high-risk patients, 6-14 days or up to 32 days in hip fracture.

Side Effects

Hip-fracture, hip-replacement, or knee-replacement surgery: Anaemia, fever, nausea, oedema, constipation, rash, vomiting, insomnia, increased wound drainage, hypokalaemia, UTI, dizziness, purpura, hypotension, confusion, bullous eruption, urinary retention, haematoma, major bleeding, diarrhoea, dyspepsia, post-op haemorrhage, and headache. Treatment of venous thromboembolism: Constipation, headache, insomnia, fever, nausea, UTI, and coughing. Abdominal surgery: Post-op wound infection and haemorrhage, fever, surgical site reaction, anaemia, HTN, pneumonia, vomiting.

Precaution

Patient with increased risk of haemorrhage (e.g. congenital or acquired bleeding disorders, history or active Gl ulceration, intracranial haemorrhage, recent brain, spinal or ophth surgery)

Interaction

Increased risk of bleeding with (e.g. desirudin, fibrinolytic drugs, glycoprotein IIb/IIIa-receptor antagonists, heparin, heparinoids or LMWH).

Food Interaction

  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include ginseng, ginkgo, ginger, and garlic.

Volume of Distribution

  • 7 - 11 L (healthy adults), distributed primarily in blood

Half Life

17-21 hours

Pregnancy & Breastfeeding use

Pregnancy Category B. Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).

Lactation: Unknown whether drug is excreted in milk; use with caution

Contraindication

Hypersensitivity. Active clinically significant bleeding, acute bacterial endocarditis.

Storage Condition

Store below 25° C. Do not freeze.

Innovators Monograph

Arixtra contains Fondaparinux see full prescribing information from innovator Monograph